Introduction
The disease now most frequently referred to as pseudotumor cerebri syndrome (PTCS), according to the most recent diagnostic criteria, 1 has been known by various names since its first clinical descriptions: pseudotumor cerebri, benign intracranial hypertension (BIH), and idiopathic intracranial hypertension (IIH). 2 These terms were introduced, respectively, by Nonne, 3 Foley, 4 and Buchheit et al. 5 The variation in nomenclature reflects the unclear etiology of this syndrome. From a historical point of view, the initial recognition of the disease depended on the following two critical steps: (1) invention of the ophthalmoscope by von Helmholtz in 1851 6 and its application in medical practice and (2) introduction by Quincke 7 of lumbar puncture, a technique that finally lead to rigorous measurement of the cerebrospinal fluid (CSF) pressure.
Earliest Descriptions of Pseudotumor Cerebri Syndrome
Authors had previously summarized the first description of this syndrome. 8, 9 One historic key manuscript is a monograph that focused on diseases of the optic nerve, published by The Transactions of the Ophthalmological Society, United Kingdom, in 1880. 10 At that time lumbar puncture was not yet utilized to assess the CSF opening pressure, which later became a fundamental criterion in the diagnosis of PTCS. The earliest descriptions of the PTCS syndrome, lacking the evaluation of CSF pressure, might be regarded as presumptive.
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Abstract
The terms "pseudotumor cerebri" and "benign intracranial hypertension," respectively, introduced by Nonne in 1904 and Foley in 1955, were originally used to describe patients with raised intracranial pressure in whom no tumor was found and whose course was considered to be relatively benign. In the modern era of medicine, the natural history of this condition has proved to be not always benign, as some patients with "benign intracranial hypertension" developed permanent blindness. Therefore, Buchheit in 1969 challenged the terms "benign" and "pseudotumor" and the denomination was then changed to "idiopathic intracranial hypertension." The recently updated diagnostic criteria for this syndrome reintroduced the original terminology and proposed to define the condition as "pseudotumor cerebri syndrome." The aim of this umbrella term is to encompass all the potential etiologies, primary and secondary, of increased intracranial pressure not associated with intracranial mass and/or anomalies of the brain parenchyma. In this article, we briefly review the history of pseudotumor cerebri syndrome.
However, some of the early reports were highly suggestive of PTCS, because of the description of the typical symptoms (e.g., headache, diplopia) in the context of specific funduscopic findings (i.e., papilledema) on the background of known PTCS-related risk factors (e.g., female gender, obesity, endocrine derangements). 10 Notably, in the 19th century, papilledema was usually referred to as optic neuritis.
8,11
From a long chapter published in 1880, 10 we know that Dr.
Hughlings Jackson 10 mentioned reports regarding "…a recoverable optic neuritis in young women suffering from uterine derangement…." In 1881, Gowers 12 described "optic neuritis," likely associated with iron deficiency anemia, a disorder now identified as an important risk factor for PTCS. In an article published in 1900, 13 Williamson and Quincke was the first to characterize anaphylaxis-related angioedema, a condition that was later defined as "Quincke edema." Quincke was also the pioneer of lumbar puncture: he described this procedure at the 10th Congress of Internal reported 10 cases suggestive of PTCS (seven females, three males) and remarked on the female preponderance. Max Nonne (►Fig. 4) was a German neurologist in Hamburg. His most important mentor was Wilhelm Heinrich Erb, the neurologist who first described brachial plexus palsy, also known as "Erb-Duchenne" palsy. In the history of PTCS, Nonne had the distinction of introducing his original work by the still-remaining term "pseudotumor cerebri" (►Fig. 5); this term described the constellation of signs and symptoms related to raised ICP but without any intracranial tumor. that an "increased ICP due to the presence of an excess of normal CSF" might follow a middle ear disease which impairs sinus venous drainage. He, therefore, defined this condition as "otitic hydrocephalus," reflecting the increase in CSF volume in the ventricular system. 8 He also recommended diversion of CSF by lumbar puncture as the best treatment choice in these patients.
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In subsequent years, the introduction of radiological techniques, such as ventriculography and angiography, allowed the exclusion of any significant expansion in the ventricular system of these patients. 8 In fact, Dyke and Davidoff 21 were the first to describe a series of adult and pediatric patients, with signs and symptoms suggestive of PTCS, in whom the lack of any ventricular dilatation on ventriculography was demonstrated. They used the term "hypertensive meningeal hydrops" 21 to define the condition of intracranial hypertension characterized by normal findings on ventriculography, in place of the term "otitic hydrocephalus" coined by Symonds. Dandy 22 also reported a large series of patients with signs and symptoms of intracranial hypertension in whom ventriculography showed the absence of ventricular dilatation. He, therefore, confirmed the conclusion of Dyke and Davidoff. Dandy used the term "intracranial pressure without brain tumor" to describe the disease and was the first to propose diagnostic criteria for this condition. 23 He also hypothesized on the underlying pathophysiology and proposed that changes in cerebral circulation were responsible for the raised ICP, rather than an increase of CSF volume. The first author who recognized a possible metabolicendocrine pathophysiological basis for the condition was Thomas 24 in 1933; he understood that obese young women were particularly prone to develop this raised ICP syndrome, likely, due to some endocrine disturbances affecting CSF and cerebral circulation dynamics. Joynt and Sahs 25 in 1957 demonstrated intracellular and extracellular edema on brain biopsy samples obtained from patients with raised ICP syndrome. Following their study, there was a growing perception of cerebral edema as the cause of intracranial hypertension. Accordingly, diuretics (acetazolamide) and corticosteroids were started in the treatment of these patients. Foley 4 in 1955 introduced the term "BIH," which became the most commonly term used to define this condition in the next several decades. In the subsequent years, with progress in neuro-ophthalmological examinations, the natural history of this condition proved to be not always benign, as some patients with "BIH" developed permanent blindness; consequently, the conventional designation at that time was changed to "IIH." 5 Ironically, in recent years, the nomenclature of this syndrome has been changed from "IIH" to "PTCS,"
1 the original term used by Nonne more than a century ago.
Notably, in 1955, Foley outlined some of the peculiar findings of PTCS: "The most important symptoms being headache of moderate degree, obscurations of vision, diplopia, and sometimes tinnitus; marked papilledema and abducens palsies are the only signs, the CSF is normal in composition and the prognosis is almost invariably good, the condition subsiding within a few weeks or months." Interestingly, Foley was also interested in explaining the underlying pathophysiology of the syndrome and in 1955 suggested that: "…an underlying endocrine imbalance, with presumably a disturbance of electrolytes, is in some way connected with the alteration of intracranial pressure."
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These concepts became meaningful again in contemporary times. In fact, recently great attention has been directed toward the role of CSF electrolyte imbalances due to endocrine derangements in PTCS. Indeed, some authors suggest that an impaired endocrine-metabolic homeostasis plays an universal etiological role in explaining most cases of primary PTCS related to well known risk factors (e.g., female gender, obesity, adrenal disorders, recombinant growth hormone therapy, and vitamin A imbalance). [26] [27] [28] However, further studies are needed to explain the elevation of ICP in this historically mysterious but yet fascinating and challenging disease.
